Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.

Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus.

A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members.

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses.

Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus.

The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week.

K. Dane Wittrup, PhD, a pioneer in protein engineering technologies who has helped accelerate development of antibody therapies for cancer, will deliver the next Flexner Discovery Lecture on Thursday, March 22.